Anaplastic Large Cell Lymphoma Therapeutics-Asia Pacific Market Status and Trend Report 2013-2023
Report Summary
Anaplastic Large Cell Lymphoma Therapeutics-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anaplastic Large Cell Lymphoma Therapeutics industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Asia Pacific and Regional Market Size of Anaplastic Large Cell Lymphoma Therapeutics 2013-2017, and development forecast 2018-2023
Main market players of Anaplastic Large Cell Lymphoma Therapeutics in Asia Pacific, with company and product introduction, position in the Anaplastic Large Cell Lymphoma Therapeutics market
Market status and development trend of Anaplastic Large Cell Lymphoma Therapeutics by types and applications
Cost and profit status of Anaplastic Large Cell Lymphoma Therapeutics, and marketing status
Market growth drivers and challenges
The report segments the Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics market as:
Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
China
Japan
Korea
India
Southeast Asia
Australia
Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
AKR-303
AZD-3463
Brentuximab Vedotin
CEP-28122
Others
Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
In-Patient
Out-Patient
Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics Market: Players Segment Analysis (Company and Product introduction, Anaplastic Large Cell Lymphoma Therapeutics Sales Volume, Revenue, Price and Gross Margin):
Akron Molecules AG
AstraZeneca Plc
Bayer AG
Celon Pharma Sp. z o.o.
Pfizer Inc.
Sareum Holdings Plc
Seattle Genetics, Inc.
Teva Pharmaceutical Industries Limited
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Anaplastic Large Cell Lymphoma Therapeutics-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anaplastic Large Cell Lymphoma Therapeutics industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Asia Pacific and Regional Market Size of Anaplastic Large Cell Lymphoma Therapeutics 2013-2017, and development forecast 2018-2023
Main market players of Anaplastic Large Cell Lymphoma Therapeutics in Asia Pacific, with company and product introduction, position in the Anaplastic Large Cell Lymphoma Therapeutics market
Market status and development trend of Anaplastic Large Cell Lymphoma Therapeutics by types and applications
Cost and profit status of Anaplastic Large Cell Lymphoma Therapeutics, and marketing status
Market growth drivers and challenges
The report segments the Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics market as:
Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
China
Japan
Korea
India
Southeast Asia
Australia
Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
AKR-303
AZD-3463
Brentuximab Vedotin
CEP-28122
Others
Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
In-Patient
Out-Patient
Asia Pacific Anaplastic Large Cell Lymphoma Therapeutics Market: Players Segment Analysis (Company and Product introduction, Anaplastic Large Cell Lymphoma Therapeutics Sales Volume, Revenue, Price and Gross Margin):
Akron Molecules AG
AstraZeneca Plc
Bayer AG
Celon Pharma Sp. z o.o.
Pfizer Inc.
Sareum Holdings Plc
Seattle Genetics, Inc.
Teva Pharmaceutical Industries Limited
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS
1.1 Definition of Anaplastic Large Cell Lymphoma Therapeutics in This Report
1.2 Commercial Types of Anaplastic Large Cell Lymphoma Therapeutics
1.2.1 AKR-303
1.2.2 AZD-3463
1.2.3 Brentuximab Vedotin
1.2.4 CEP-28122
1.2.5 Others
1.3 Downstream Application of Anaplastic Large Cell Lymphoma Therapeutics
1.3.1 In-Patient
1.3.2 Out-Patient
1.4 Development History of Anaplastic Large Cell Lymphoma Therapeutics
1.5 Market Status and Trend of Anaplastic Large Cell Lymphoma Therapeutics 2013-2023
1.5.1 China Anaplastic Large Cell Lymphoma Therapeutics Market Status and Trend 2013-2023
1.5.2 Regional Anaplastic Large Cell Lymphoma Therapeutics Market Status and Trend 2013-2023
CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Anaplastic Large Cell Lymphoma Therapeutics in China 2013-2017
2.2 Consumption Market of Anaplastic Large Cell Lymphoma Therapeutics in China by Regions
2.2.1 Consumption Volume of Anaplastic Large Cell Lymphoma Therapeutics in China by Regions
2.2.2 Revenue of Anaplastic Large Cell Lymphoma Therapeutics in China by Regions
2.3 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in China by Regions
2.3.1 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in North China 2013-2017
2.3.2 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in Northeast China 2013-2017
2.3.3 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in East China 2013-2017
2.3.4 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in Central & South China 2013-2017
2.3.5 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in Southwest China 2013-2017
2.3.6 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in Northwest China 2013-2017
2.4 Market Development Forecast of Anaplastic Large Cell Lymphoma Therapeutics in China 2018-2023
2.4.1 Market Development Forecast of Anaplastic Large Cell Lymphoma Therapeutics in China 2018-2023
2.4.2 Market Development Forecast of Anaplastic Large Cell Lymphoma Therapeutics by Regions 2018-2023
CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole China Market Status by Types
3.1.1 Consumption Volume of Anaplastic Large Cell Lymphoma Therapeutics in China by Types
3.1.2 Revenue of Anaplastic Large Cell Lymphoma Therapeutics in China by Types
3.2 China Market Status by Types in Major Countries
3.2.1 Market Status by Types in North China
3.2.2 Market Status by Types in Northeast China
3.2.3 Market Status by Types in East China
3.2.4 Market Status by Types in Central & South China
3.2.5 Market Status by Types in Southwest China
3.2.6 Market Status by Types in Northwest China
3.3 Market Forecast of Anaplastic Large Cell Lymphoma Therapeutics in China by Types
CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics in China by Downstream Industry
4.2 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Major Countries
4.2.1 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in North China
4.2.2 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Northeast China
4.2.3 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in East China
4.2.4 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Central & South China
4.2.5 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Southwest China
4.2.6 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Northwest China
4.3 Market Forecast of Anaplastic Large Cell Lymphoma Therapeutics in China by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS
5.1 China Economy Situation and Trend Overview
5.2 Anaplastic Large Cell Lymphoma Therapeutics Downstream Industry Situation and Trend Overview
CHAPTER 6 ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA
6.1 Sales Volume of Anaplastic Large Cell Lymphoma Therapeutics in China by Major Players
6.2 Revenue of Anaplastic Large Cell Lymphoma Therapeutics in China by Major Players
6.3 Basic Information of Anaplastic Large Cell Lymphoma Therapeutics by Major Players
6.3.1 Headquarters Location and Established Time of Anaplastic Large Cell Lymphoma Therapeutics Major Players
6.3.2 Employees and Revenue Level of Anaplastic Large Cell Lymphoma Therapeutics Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Akron Molecules AG
7.1.1 Company profile
7.1.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.1.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Akron Molecules AG
7.2 AstraZeneca Plc
7.2.1 Company profile
7.2.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.2.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca Plc
7.3 Bayer AG
7.3.1 Company profile
7.3.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.3.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Bayer AG
7.4 Celon Pharma Sp. z o.o.
7.4.1 Company profile
7.4.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.4.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Celon Pharma Sp. z o.o.
7.5 Pfizer Inc.
7.5.1 Company profile
7.5.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.5.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer Inc.
7.6 Sareum Holdings Plc
7.6.1 Company profile
7.6.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.6.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Sareum Holdings Plc
7.7 Seattle Genetics, Inc.
7.7.1 Company profile
7.7.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.7.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Seattle Genetics, Inc.
7.8 Teva Pharmaceutical Industries Limited
7.8.1 Company profile
7.8.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.8.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Limited
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS
8.1 Industry Chain of Anaplastic Large Cell Lymphoma Therapeutics
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS
9.1 Cost Structure Analysis of Anaplastic Large Cell Lymphoma Therapeutics
9.2 Raw Materials Cost Analysis of Anaplastic Large Cell Lymphoma Therapeutics
9.3 Labor Cost Analysis of Anaplastic Large Cell Lymphoma Therapeutics
9.4 Manufacturing Expenses Analysis of Anaplastic Large Cell Lymphoma Therapeutics
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Anaplastic Large Cell Lymphoma Therapeutics in This Report
1.2 Commercial Types of Anaplastic Large Cell Lymphoma Therapeutics
1.2.1 AKR-303
1.2.2 AZD-3463
1.2.3 Brentuximab Vedotin
1.2.4 CEP-28122
1.2.5 Others
1.3 Downstream Application of Anaplastic Large Cell Lymphoma Therapeutics
1.3.1 In-Patient
1.3.2 Out-Patient
1.4 Development History of Anaplastic Large Cell Lymphoma Therapeutics
1.5 Market Status and Trend of Anaplastic Large Cell Lymphoma Therapeutics 2013-2023
1.5.1 China Anaplastic Large Cell Lymphoma Therapeutics Market Status and Trend 2013-2023
1.5.2 Regional Anaplastic Large Cell Lymphoma Therapeutics Market Status and Trend 2013-2023
CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Anaplastic Large Cell Lymphoma Therapeutics in China 2013-2017
2.2 Consumption Market of Anaplastic Large Cell Lymphoma Therapeutics in China by Regions
2.2.1 Consumption Volume of Anaplastic Large Cell Lymphoma Therapeutics in China by Regions
2.2.2 Revenue of Anaplastic Large Cell Lymphoma Therapeutics in China by Regions
2.3 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in China by Regions
2.3.1 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in North China 2013-2017
2.3.2 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in Northeast China 2013-2017
2.3.3 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in East China 2013-2017
2.3.4 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in Central & South China 2013-2017
2.3.5 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in Southwest China 2013-2017
2.3.6 Market Analysis of Anaplastic Large Cell Lymphoma Therapeutics in Northwest China 2013-2017
2.4 Market Development Forecast of Anaplastic Large Cell Lymphoma Therapeutics in China 2018-2023
2.4.1 Market Development Forecast of Anaplastic Large Cell Lymphoma Therapeutics in China 2018-2023
2.4.2 Market Development Forecast of Anaplastic Large Cell Lymphoma Therapeutics by Regions 2018-2023
CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole China Market Status by Types
3.1.1 Consumption Volume of Anaplastic Large Cell Lymphoma Therapeutics in China by Types
3.1.2 Revenue of Anaplastic Large Cell Lymphoma Therapeutics in China by Types
3.2 China Market Status by Types in Major Countries
3.2.1 Market Status by Types in North China
3.2.2 Market Status by Types in Northeast China
3.2.3 Market Status by Types in East China
3.2.4 Market Status by Types in Central & South China
3.2.5 Market Status by Types in Southwest China
3.2.6 Market Status by Types in Northwest China
3.3 Market Forecast of Anaplastic Large Cell Lymphoma Therapeutics in China by Types
CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics in China by Downstream Industry
4.2 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Major Countries
4.2.1 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in North China
4.2.2 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Northeast China
4.2.3 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in East China
4.2.4 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Central & South China
4.2.5 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Southwest China
4.2.6 Demand Volume of Anaplastic Large Cell Lymphoma Therapeutics by Downstream Industry in Northwest China
4.3 Market Forecast of Anaplastic Large Cell Lymphoma Therapeutics in China by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS
5.1 China Economy Situation and Trend Overview
5.2 Anaplastic Large Cell Lymphoma Therapeutics Downstream Industry Situation and Trend Overview
CHAPTER 6 ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA
6.1 Sales Volume of Anaplastic Large Cell Lymphoma Therapeutics in China by Major Players
6.2 Revenue of Anaplastic Large Cell Lymphoma Therapeutics in China by Major Players
6.3 Basic Information of Anaplastic Large Cell Lymphoma Therapeutics by Major Players
6.3.1 Headquarters Location and Established Time of Anaplastic Large Cell Lymphoma Therapeutics Major Players
6.3.2 Employees and Revenue Level of Anaplastic Large Cell Lymphoma Therapeutics Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Akron Molecules AG
7.1.1 Company profile
7.1.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.1.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Akron Molecules AG
7.2 AstraZeneca Plc
7.2.1 Company profile
7.2.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.2.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca Plc
7.3 Bayer AG
7.3.1 Company profile
7.3.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.3.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Bayer AG
7.4 Celon Pharma Sp. z o.o.
7.4.1 Company profile
7.4.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.4.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Celon Pharma Sp. z o.o.
7.5 Pfizer Inc.
7.5.1 Company profile
7.5.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.5.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer Inc.
7.6 Sareum Holdings Plc
7.6.1 Company profile
7.6.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.6.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Sareum Holdings Plc
7.7 Seattle Genetics, Inc.
7.7.1 Company profile
7.7.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.7.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Seattle Genetics, Inc.
7.8 Teva Pharmaceutical Industries Limited
7.8.1 Company profile
7.8.2 Representative Anaplastic Large Cell Lymphoma Therapeutics Product
7.8.3 Anaplastic Large Cell Lymphoma Therapeutics Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Limited
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS
8.1 Industry Chain of Anaplastic Large Cell Lymphoma Therapeutics
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS
9.1 Cost Structure Analysis of Anaplastic Large Cell Lymphoma Therapeutics
9.2 Raw Materials Cost Analysis of Anaplastic Large Cell Lymphoma Therapeutics
9.3 Labor Cost Analysis of Anaplastic Large Cell Lymphoma Therapeutics
9.4 Manufacturing Expenses Analysis of Anaplastic Large Cell Lymphoma Therapeutics
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
